Safety and efficacy of fixed-dose combination of ledipasvir/sofosbuvir with or without ribavirin in patients with genotype 1 hepatitis C

Trial Profile

Safety and efficacy of fixed-dose combination of ledipasvir/sofosbuvir with or without ribavirin in patients with genotype 1 hepatitis C

Completed
Phase of Trial: Phase IV

Latest Information Update: 02 Apr 2018

At a glance

  • Drugs Ledipasvir/sofosbuvir (Primary) ; Ribavirin
  • Indications Hepatitis C
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 02 Apr 2018 New trial record
    • 23 Mar 2018 Results published in the Alimentary Pharmacology and Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top